FIELD: medicine, gastroenterology.
SUBSTANCE: invention can be used for treatment of diseases associated with infection of colon intestine with microorganism C. difficile and also with formation of enterococcus colonies exhibiting resistance to vancomycin. Method involves the effective amount of pharmaceutical composition containing cover retaining its integrity during passage through digestive tract and releasing an active component in colon intestine. The composition contains lantocin as an active component, from 2 to 20% of NaCl and from 20 to 80% of cover as measured for mass of crude active cover. Invention is designated for the development of agents directed for treatment of colon intestine diseases and for suppression of potentially danger microorganisms forming colonies in colon intestine and for the development of agents for delivery of taken lantocin to colon intestine in sufficient amount to provides the effective treatment of infection focus.
EFFECT: improved treatment method.
27 cl, 8 dwg, 11 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DRUG FORM FOR DELIVERY OF MEDICATION INTO LARGE INTESTINE | 2007 |
|
RU2478372C2 |
| PHARMACEUTICAL FORM FOR DRUG DELIVERY TO THE COLON | 2007 |
|
RU2646825C2 |
| MEDICINAL FORMS ON BASIS OF BIPHOSPHONATES | 2005 |
|
RU2359678C2 |
| PHARMACEUTICAL MEDICINAL FORM, RESISTANT TO GASTRIC JUICE ACTIVITY, WHICH INCLUDES N-(2-(2-PHTHALIMIDOETOXY)ACETYL)-L-ALANYL-D-GLUTAMIC ACID (LK 423) | 2005 |
|
RU2375047C2 |
| FORMULATIONS FOR ORAL DELIVERY OF ADSORBENTS IN INTESTINE | 2016 |
|
RU2681315C2 |
| DOSAGE FORMS OF RISEDRONATE | 2005 |
|
RU2381791C2 |
| PHARMACEUTICAL DOSAGE FORMS AND COMPOSITIONS OF COLON ABSORBED PHENYLEPHRINE | 2007 |
|
RU2454225C2 |
| PANTOPRAZOLE COMPOUNDS CONSISTING OF SET OF PARTICLES | 2004 |
|
RU2361574C2 |
| PHARMACOLOGICAL COMPOSITION WITH SWELLING COATING | 2004 |
|
RU2375048C2 |
| pH-CONTROLLED PULSE DELIVERY SYSTEMS, METHODS FOR PRODUCING AND USING THEREOF | 2005 |
|
RU2412694C2 |
